Spotlight on Internal Medicine

Credits: 1.00 CME
The Changing Landscape of Immune-Based Therapies for COVID-19
Leonard H. Calabrese, DO
Vindico Medical Education

The Changing Landscape of Immune-Based Therapies for COVID-19

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 28, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Describe the clinical and immunological events underlying the natural history of COVID-19.
  • Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
  • Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.

Activity Description

The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.

Agenda

Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO

Updates on Immune-Based Therapies for the Management of Patients With COVID-19
Kevin Winthrop, MD, MPH

Considerations for Outpatient Management of Immunocompromised Patients
Cassandra Calabrese, DO

Putting it All Together: How Should We Manage Patients Hospitalized With COVID-19?
D. Clark Files, MD

Conclusion
Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


D. Clark Files, MD
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC

Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: September 29, 2021
Expires: September 28, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is hospitalists, critical care physicians, intensivists, immunologists, infectious disease specialists, pulmonologists, rheumatologists, and other health care professionals involved in the management of patients hospitalized with COVID-19 infection.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Describe the clinical and immunological events underlying the natural history of COVID-19.
  • Critically appraise the data regarding immune-based therapies for the management of hyperinflammation due to COVID-19, including glucocorticoids, Janus kinase inhibitors, and other targeted agents.
  • Describe how variables such as disease severity, timing, and immunologic endotypes should impact the management of patients hospitalized with COVID-19 infection.

Activity Description

The COVID-19 pandemic has led to a health care crisis with widespread global morbidity and mortality, spurring unprecedented levels of ongoing research for effective therapeutic strategies. A major challenge for health care providers involved in patient management is staying current on the latest evidence-based care despite the rapid influx of data. Hospitalists and other clinicians who care for hospitalized patients may rely heavily on therapies with which they are familiar, namely corticosteroids. However, immunomodulatory therapies such as Janus kinase inhibitors and interleukin-6 inhibitors provide promising options to prevent disease progression and reduce mortality risk. In this educational activity, multidisciplinary panel members review the clinical and immunological events underlying COVID-19; appraise emerging data on immunomodulatory therapies; and discuss how disease severity, timing, and immunological endotypes may impact the management of patients hospitalized with COVID-19 infection.

Agenda

Introduction and Immunopathogenesis of COVID-19
Leonard H. Calabrese, DO

Updates on Immune-Based Therapies for the Management of Patients With COVID-19
Kevin Winthrop, MD, MPH

Considerations for Outpatient Management of Immunocompromised Patients
Cassandra Calabrese, DO

Putting it All Together: How Should We Manage Patients Hospitalized With COVID-19?
D. Clark Files, MD

Conclusion
Leonard H. Calabrese, DO

Activity Chair

Leonard H. Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
Case Western Reserve University
R.J. Fasenmyer Chair of Clinical Immunology
Cleveland Clinic
Cleveland, OH

Disclosure:
Consulting Fee:
AbbVie, Bristol Myers Squibb, Crescendo, Genentech, Gilead, GlaxoSmithKline, Janssen, Lilly, Pfizer, Regeneron, Sanofi Genzyme, UCB
Speakers Bureau: AbbVie, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Regeneron, Sanofi, UCB

Faculty

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Speakers Bureau: Sanofi-Genzyme


D. Clark Files, MD
Associate Professor
Pulmonary, Critical Care, Allergy, and Immunologic Diseases
Wake Forest School of Medicine
Winston-Salem, NC

Disclosure:
Consulting Fee: California Institute of Regenerative Medicine
Data Safety Monitoring Board: Medpace


Kevin Winthrop, MD, MPH
Professor, Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Sciences University
Portland, OR

Disclosure:
Consulting Fee: Horizon, Insmed, Paratek, Red Hill Biopharma, Spero
Contracted Research: Insmed

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Lilly.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Internal Medicine Presentations

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Rapid ART Protocols As a New Standard of Care in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Rapid ART Protocols As a New Standard of Care in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation

Program Description

Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based portion of a previous symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Describe the benefits of rapid antiretroviral therapy (ART) and tactics to overcome clinician and system barriers to implementation

Program Description

Since the rapid initiation of antiretroviral therapy (ART) has become more widely available, identified barriers to more widespread adoption of this approach to HIV management—whether faced by patient, provider, or health care system—now need solutions. In this case-based portion of a previous symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal implementation of rapid ART. Faculty will guide learners on the important role of patient navigators or linkage to care coordinators in assisting patients to successfully enroll at the clinic, navigate public or private health insurance or drug assistance programs to gain access to ART, and get referrals for needed support services, including counseling or housing assistance.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Optimizing Adherence and Retention in Care in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Optimizing Adherence and Retention in Care in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens in specific subpopulations, such as women or the aging population. The proliferation of treatment-switching strategies has made therapeutic selection increasingly complex; real-world cases can provide context for education on this challenging topic.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / CNE
Postgraduate Institute for Medicine
Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Guideline Updates and Recent Therapeutic Advances in HIV

Case in Point™ Case Challenges in HIV Medicine: Benefits, Barriers, & Best Practices in an Advancing Field - Guideline Updates and Recent Therapeutic Advances in HIV

Start

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens that may necessitate a switch to 2-drug regimens. Risks and benefits of initiating treatment with a 2-drug regimen will be discussed. As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE
0.5 AMA PRA Category 1 Credit(s)
0.5 Contact Hour(s)
Released: January 8, 2021
Expires: January 8, 2022
30 minutes to complete

Statement of Commercial Support

Supported by an independent educational grant from Gilead Sciences, Inc.

Provided By

This activity is jointly provided by Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

This activity is designed to educate HIV specialists and infectious disease clinicians who are involved in the management of patients living with HIV.

Learning Objectives

Upon completion of this activity, the participant should be better able to:

  • Implement the most recent guidelines on identifying, treating, and monitoring patients with HIV
  • Optimize ART selection for treatment initiation and medication switching according to patient characteristics and comorbidities

Program Description

In this portion of a previous case-based symposium, Dr. Richard Elion, along with Drs. Eric Daar, Seble Kassaye, and Leandro Mena, will elucidate appropriate treatment approaches that integrate established, streamlined models of care and demonstrate optimal selection of ART. Demonstrating key considerations of HIV management through cases, faculty will identify and discuss aspects of care (e.g., comorbidities, polypharmacy issues, and adverse events) associated with ART regimens that may necessitate a switch to 2-drug regimens. Risks and benefits of initiating treatment with a 2-drug regimen will be discussed. As HIV care progresses and new treatment options become available for initiating and switching ART regimens, clinicians must know the data, indications, contraindications, and potential for adverse events or drug-drug interactions when individualizing treatment plans.

Within the context of these interactive cases, faculty will share relevant guideline recommendations, newly published data, and their clinical expertise.

Course Chair

Richard A. Elion, MD
Associate Clinical Professor
Department of Clinical Investigations
Whitman-Walker Health
The George Washington University
Washington, District of Columbia

Dr. Richard Elion is a clinical professor of medicine at George Washington University, as well as Research Director, HIV and HCV Research, at the Washington Health Institute, both in Washington, DC. He is the past Director of Clinical Research at Whitman-Walker Health in Washington, DC, where he focused on cutting-edge research in HIV. His tenure at Whitman-Walker Health coincided with the organization being selected in 2013 as part of the AIDS Clinical Trials Group by the National Institutes of Health. Prior to his tenure with Whitman-Walker Health, he served as Co-Director of HIV Services at Washington Free Clinic in Washington, DC, and in various research and clinical capacities in New York and Washington, DC. In addition to being an accomplished educator and clinician, Dr. Elion also develops educational programs around the United States.

Dr. Elion received his medical degree from Temple University in Philadelphia, Pennsylvania, and completed his internship and residency at Duke University in Durham, North Carolina. He also holds a master’s degree in counseling and spiritual psychology from the University of Santa Monica in Santa Monica, California.

Faculty

Eric S. Daar, MD
Chief, Division of HIV Medicine
Harbor-UCLA Medical Center
Chief, HIV Services
Lundquist Institute for Biomedical Innovation
Professor of Medicine, David Geffen School of Medicine
University of California, Los Angeles
Torrance, California

Dr. Eric Daar is Interim Chair of the Department of Medicine and Chief of the Division of HIV Medicine at the Harbor-UCLA Medical Center in Torrance, California. He is also a professor of medicine at the David Geffen School of Medicine at UCLA in Los Angeles, California, as well as an investigator for the Lundquist Institute. He earned his medical degree from Georgetown University School of Medicine in Washington, DC, and completed his internship, residency, and fellowship at Cedars-Sinai Medical Center in Los Angeles. His clinical and research interests include a vast range of HIV-related issues that include pathogenesis and treatment of acute and chronic HIV infection, HIV/HCV coinfection, complications of HIV, and novel strategies for assessing and enhancing adherence to therapy. He has authored numerous articles that have been published in peer-reviewed journals and textbooks.

Seble G. Kassaye, MD, MS
Associate Professor of Medicine
Department of Medicine
Division of Infectious Diseases
Georgetown University
Washington, District of Columbia

Dr. Seble Kassaye earned her medical degree from the University of Chicago Pritzker School of Medicine in Illinois before completing her residency training in internal medicine and pediatrics at Mount Sinai Medical Center in New York and her infectious disease fellowship at Stanford University Hospital in California. She also completed a master’s degree in epidemiology at Stanford University. Dr. Kassaye joined the faculty at Georgetown University in December 2012.

Dr. Kassaye’s investigative focus is on clinical and translational research related to HIV with the objective of increasing access to and uptake of effective HIV treatment and prevention modalities by the most at-risk and indigent populations. As the principal investigator of the DC MACS/WIHS Combined Cohort Study, she aims to understand how HIV contributes to comorbidities, metabolic and cardiovascular complications, and long-term treatment outcomes, along with social, psychological, and cognitive effects of HIV. Dr. Kassaye has been a practicing physician in Washington, DC, for almost a decade, including at a tertiary care academic center as well as a community-based clinic in the ward with highest HIV prevalence in southeast DC. Most of her US-based research projects are driven by questions that she identifies in the context of providing care to a highly indigent and socially vulnerable population.

Leandro A. Mena, MD, MPH
Chair and Professor of Population Health Science
Professor of Medicine, Division of Infectious Diseases
Director, Center for HIV/AIDS Research, Education and Policy
The University of Mississippi Medical Center
Jackson, Mississippi

Dr. Leandro Mena is a clinician-researcher and public health advocate with expertise in the prevention and clinical management of sexually transmitted diseases (STDs) and HIV. He is founding chair of the Department of Population Health Science at the University of Mississippi Medical Center, John D. Bower School of Population Health, and professor of medicine in the Division of Infectious Diseases. He directs the Center for HIV/AIDS Research, Education and Policy at the Myrlie Evers-Williams Institute for Elimination of Health Disparities, and serves as the STD Medical Director for the state of Mississippi. He is also the Medical Director of the Five Points Clinic (Jackson’s public STD clinic) and cofounded Open Arms Healthcare Center (first LGBT clinic in Mississippi).

In recognition of his work developing a model program of culturally competent HIV prevention and care for Black men who have sex with men, which is being replicated in other clinics of the country, he was awarded the 2016 Achievement Award by the Gay and Lesbian Medical Association (GLMA). Board certified in infectious diseases, Dr. Mena is a research fellow with the Rural Center for STD/HIV Prevention (Indiana University). His interests include understanding the dynamics of HIV transmission in racial/ethnic, gender, and sexual minorities as well as the development and provision of culturally competent quality health services to these populations.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Physician Continuing Medical Education

The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in this activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hour(s).

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Richard A. Elion, MD
Grants/Research support: Gilead Sciences, Inc., ViiV Healthcare
Honoraria: Gilead Sciences, Inc., ViiV Healthcare
Speakers Bureau: Gilead Sciences, Inc.

Eric S. Daar, MD
Consulting Fees: Genentech Inc., Gilead Sciences, Inc., Merck Co., Inc.
Contracted Research: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare

Seble G. Kassaye, MD, MS
Nothing to disclose

Leandro A. Mena, MD, MPH
Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare
Contracted Research: Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Roche, TaiMed Biologics, ViiV Healthcare

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Instructions to Receive Credit

There are no fees for participating and receiving CE credit for this activity. Participants must read the learning objectives and faculty disclosures and participate in the educational activity. 

A statement of credit will be issued upon receipt of a completed posttest (with a score of 70% or higher) and an activity evaluation form at the conclusion of the activity.

If you have questions regarding the receipt of your certificate, please contact PIM via email at inquiries@pimed.com.

Media

Internet

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.50 CME / CE
Clinical Care Options
Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices

Managing Diabetic Eye Disease in the Latino/Hispanic Community: A Case-Based Review of Best Practices

Start

Activity Details

Free CME/CE
0.5 AMA PRA Category 1 Credit(s)™/
AAPA Category 1 CME credit(s)
Released: January 8, 2021
Expires: January 7, 2022
30 minutes to complete

Accredited By

Jointly Provided By

Target Audience

This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.

Learning Objectives

  • Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
  • Outline risks associated with delayed intervention in patients with diabetic eye disease.
  • Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
  • Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.

Activity Description

This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.

Statement of Educational Need

The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1

With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.

1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.

2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682

3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009

Agenda

  • Latino/Hispanic population growth in the US
  • Healthcare disparities
  • Diabetic eye disease risk and complications
  • Eye exam frequency recommendations
  • Triage and other practical diagnostic challenges
  • Screening and exam recommendations
  • Evidence-based best practices for diagnosing diabetic eye disease
  • The most commonly performed procedure in ophthalmology
  • Anti-VEGF treatments for DME
  • Anti-VEGF treatments for DR
  • Anti-VEGF treatments for NPDR

Faculty

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Conflict of Interest Policy/Disclosure Statement

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.

Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com

Activity Details

Free CME/CE
0.5 AMA PRA Category 1 Credit(s)™/
AAPA Category 1 CME credit(s)
Released: January 8, 2021
Expires: January 7, 2022
30 minutes to complete

Accredited By

Jointly Provided By

Target Audience

This program is intended for physicians, physician assistants, nurse practitioners, and other healthcare providers who care for patients with diabetic eye disease in the Latino/Hispanic community.

Learning Objectives

  • Discuss the unmet need for improved diabetic eye care in the Latino/Hispanic community.
  • Outline risks associated with delayed intervention in patients with diabetic eye disease.
  • Describe standards of care and preferred practice patterns for screening and diagnosing diabetic eye disease.
  • Explain the benefits of timely anti-VEGF treatments for patients with diabetic macular edema and diabetic retinopathy.

Activity Description

This program aims to raise awareness among primary care physicians, nurse practitioners and physician assistants—arming them with strategies to identify, evaluate and address key biological, social, psychological and social factors that influence the development and course of retinal disease in the Latino/Hispanic population. As front line providers, primary care is uniquely positioned to direct patients to necessary tertiary care services. Throughout this interactive learning opportunity, participants will learn about the unmet need for diabetic eye care and the risks associated with delayed intervention. Best practices in screening, diagnosis, and referral also will be described. Finally, participants will become well acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy.

Statement of Educational Need

The primary care visit is an essential touch-point at which diabetic patients can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. Unfortunately, countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The Latino/Hispanic population is at particularly high risk. This group, which is expected to reach 30% of the total US population by 2050, is more likely to develop diabetes-related complications, often has a higher mortality rate, and receives lower quality of health care when compared to mainstream groups.1

With so many Hispanics failing to adhere to the recommendations of the American Diabetes Association (ADA), prompt and effective intervention is essential.2,3 Indeed, one of the most critical needs in diabetic care is not regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. This program will utilize a case-based approach to optimize diabetes patient education for the Latino/Hispanic community, promote adherence to recommended eye exams and encourage earlier-stage treatment when indicated.

1Caballero AE. Transcultural diabetes care: a call for addressing the patient as a whole. Endocr Pract. 2019 Jul;25(7):766-768.

2Hu J, Wallace DC, McCoy TP, Amirehsani KA. A family-based diabetes intervention for Hispanic adults and their family members. Diabetes Educ. 2014;40(1):48–59. doi:10.1177/0145721713512682

3Faber AJ. Agency for Healthcare Research and Quality, Minority health: Recent findings. 2009

Agenda

  • Latino/Hispanic population growth in the US
  • Healthcare disparities
  • Diabetic eye disease risk and complications
  • Eye exam frequency recommendations
  • Triage and other practical diagnostic challenges
  • Screening and exam recommendations
  • Evidence-based best practices for diagnosing diabetic eye disease
  • The most commonly performed procedure in ophthalmology
  • Anti-VEGF treatments for DME
  • Anti-VEGF treatments for DR
  • Anti-VEGF treatments for NPDR

Faculty

Rishi P. Singh, MD
Staff Physician
Cole Eye Institute
Cleveland Clinic Foundation
Associate Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, Ohio

Conflict of Interest Policy/Disclosure Statement

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funding by Apellis and Grayburg. Dr Singh also discloses he receives consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon.

Clinical Care Options’ Planners and Managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and Infinity Medical Education. Clinical Care Options, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credit. Approval is valid until January 7, 2022. PAs should only claim commensurate with the extent of their participation.

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Anne Rojas
President
Infinity Medical Education, LLC
Anne.rojas@infinitymeded.com

1.00 CME
Integrity Continuing Education, Inc.
Redefining the Diagnosis and Therapy of COPD: Lessons from COPDGene, GOLD Reports, and Precision Medicine

Redefining the Diagnosis and Therapy of COPD: Lessons from COPDGene, GOLD Reports, and Precision Medicine

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 21, 2020
Expires: December 21, 2021
1 hour to complete

Accredited By

Target Audience

This educational activity has been designed for pulmonologists and other clinicians involved in the management of patients with COPD.

Learning Objectives

  • Identify clinical, functional, and radiological characteristics that can facilitate earlier COPD diagnosis and recognition of those who can benefit from available therapies​
  • Recognize the importance of smoking cessation, early treatment, and other prevention approaches in alleviating the burden of COPD​
  • Apply precision medicine-based approaches and current GOLD strategy to improve individualized treatment of COPD​
  • Describe the ongoing evolution of COPD diagnosis and its management in the era of COVID-19

Statement of Educational Need

Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, clinical practice has consistently underdiagnosed and undertreated this condition. As a result, patients with COPD continue to be associated with a poor quality of life, and there has remained an unmet need to improve its continuum of care. Recent data have shown that, using new criteria and methodologies, the definition of COPD can be broadened to include patients who would have been excluded from a previously characterized definite diagnosis. In addition, earlier treatment of such patients with pharmacologic, non-pharmacologic, and preventive strategies would be of benefit in reducing the burden of symptoms. Furthermore, implementation of updated guidelines and novel precision medicine-based approaches to individualize management of diverse patients with COPD will also be critical to improving outcomes. This continuing education program will clarify the clinical implications of new perspectives in the diagnosis, treatment, and management of this complicated disease.

Faculty

Gerard Criner, MD, FACP, FACCP
Professor of Medicine
Chair, Department of Thoracic Medicine & Surgery
Lewis Katz School of Medicine
Temple University Co-Director, Center for Inflammation and Lung Research
Medical Director, Pulmonary Service Line
Temple University Hospital
Philadelphia, Pennsylvania


Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York


Ruth Tal-Singer, PhD
President and Chief Scientific Officer
COPD Foundation
Washington, District of Columbia
President, TALSi Translational Medicine Consulting, LLC
Greater Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Gerard Criner, MD, FACP, FACCP
Consulting Fees: Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, Eolo Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Philips Respironics, Respivant Sciences, The Implementation Group, Verona Pharma ​

Fernando J. Martinez, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, CSL Behring, Genentech, GlaxoSmithKline, Sanofi/Regeneron​
Contracted Research: Afferent/Merck, Bayer, Biogen, Gilead, GlaxoSmithKline, Respivant Science, ProMedior/Roche, Veracyte​

Ruth Tal-Singer, PhD 
Former employee and current shareholder of GSK and reports personal fees from Vocalis Health, ImmunoMet, and Ena Respiratory. 

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of December 21, 2020 through December 21, 2021, participants must:

  • Read the learning objectives and faculty disclosures 
  • Complete the pretest
  • Study the educational activity 
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from AstraZeneca.

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: December 21, 2020
Expires: December 21, 2021
1 hour to complete

Accredited By

Target Audience

This educational activity has been designed for pulmonologists and other clinicians involved in the management of patients with COPD.

Learning Objectives

  • Identify clinical, functional, and radiological characteristics that can facilitate earlier COPD diagnosis and recognition of those who can benefit from available therapies​
  • Recognize the importance of smoking cessation, early treatment, and other prevention approaches in alleviating the burden of COPD​
  • Apply precision medicine-based approaches and current GOLD strategy to improve individualized treatment of COPD​
  • Describe the ongoing evolution of COPD diagnosis and its management in the era of COVID-19

Statement of Educational Need

Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, clinical practice has consistently underdiagnosed and undertreated this condition. As a result, patients with COPD continue to be associated with a poor quality of life, and there has remained an unmet need to improve its continuum of care. Recent data have shown that, using new criteria and methodologies, the definition of COPD can be broadened to include patients who would have been excluded from a previously characterized definite diagnosis. In addition, earlier treatment of such patients with pharmacologic, non-pharmacologic, and preventive strategies would be of benefit in reducing the burden of symptoms. Furthermore, implementation of updated guidelines and novel precision medicine-based approaches to individualize management of diverse patients with COPD will also be critical to improving outcomes. This continuing education program will clarify the clinical implications of new perspectives in the diagnosis, treatment, and management of this complicated disease.

Faculty

Gerard Criner, MD, FACP, FACCP
Professor of Medicine
Chair, Department of Thoracic Medicine & Surgery
Lewis Katz School of Medicine
Temple University Co-Director, Center for Inflammation and Lung Research
Medical Director, Pulmonary Service Line
Temple University Hospital
Philadelphia, Pennsylvania


Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York


Ruth Tal-Singer, PhD
President and Chief Scientific Officer
COPD Foundation
Washington, District of Columbia
President, TALSi Translational Medicine Consulting, LLC
Greater Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Gerard Criner, MD, FACP, FACCP
Consulting Fees: Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, Eolo Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Philips Respironics, Respivant Sciences, The Implementation Group, Verona Pharma ​

Fernando J. Martinez, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, CSL Behring, Genentech, GlaxoSmithKline, Sanofi/Regeneron​
Contracted Research: Afferent/Merck, Bayer, Biogen, Gilead, GlaxoSmithKline, Respivant Science, ProMedior/Roche, Veracyte​

Ruth Tal-Singer, PhD 
Former employee and current shareholder of GSK and reports personal fees from Vocalis Health, ImmunoMet, and Ena Respiratory. 

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of December 21, 2020 through December 21, 2021, participants must:

  • Read the learning objectives and faculty disclosures 
  • Complete the pretest
  • Study the educational activity 
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from AstraZeneca.

0.50 CME
The France Foundation
PILOT™ 2020 Conference Coverage – Practical Applications From What We Heard at Virtual ACR

PILOT™ 2020 Conference Coverage – Practical Applications From What We Heard at Virtual ACR

Start

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: December 10, 2020
Expires: December 9, 2021
30 minutes to complete

Accredited By

Target Audience

Rheumatologists, dermatologists, primary care providers, pulmonologists, and other health care providers who manage patients with ILD.

Learning Objectives

SSc-ILD

  • Diagnose SSc-ILD based on clinical impression and appropriate diagnostic tests
  • Discuss prevailing “dogma” for the diagnosis and management of SSc-ILD
  • Describe extrapulmonary manifestations and common comorbidities of SSc-ILD
  • Evaluate therapeutic options for the management of SSc-ILD in terms of efficacy and safety

PF-ILD

  • Identify the ILDs most commonly associated with a progressive fibrosing phenotype (PF-ILD)
  • Describe the signs and symptoms associated with PF-ILD
  • Describe the clinical course of a PF-ILD
  • Review the general therapeutic options available for the management of PF-ILDs
  • Discuss emerging therapeutic options for the management of PF-ILDs

Activity Description

Video reports on clinical trials, posters, and sessions from the virtual ACR 2020 conference. Faculty discuss the latest on systemic sclerosis-ILD, progressive fibrosing-ILD, and the implication of this information on current clinical practices for clinicians.

Faculty

S. Sam Lim, MD, MPH
Professor of Medicine and Epidemiology
Clinical Director, Division of Rheumatology
Emory University
Atlanta, GA


Elizabeth Volkmann, MD, MS
Clinical Instructor
Department of Medicine, Division of Rheumatology
University of California, Los Angeles
Los Angeles, CA


Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center
at University of California, Los Angeles
Los Angeles, CA

Conflict of Interest Policy/Disclosure Statement

The following staff at TFF report that they have relevant financial relationships to disclose:

  • Patrick Harty, PhD, reports that his spouse is employed by Pfizer, Inc. and they hold stock in Pfizer, Inc.

All other planners, reviewers, editors, staff, CME committee, and other members at TFF who control content have no relevant financial relationships to disclose.
 
The following faculty report that they have no relevant financial relationships to disclose:

  • Daniel J. Wallace, MD, FACP, MACR, has nothing to disclose

The following faculty report that they have relevant financial relationships to disclose:

  • S. Sam Lim, MD, MPH, has served as a consultant on the UCB Medical Advisory Board
  • Elizabeth Volkmann, MD, MS, has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc. and Forbius

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. This provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME
0.5 AMA PRA Category 1 Credit(s)
Released: December 10, 2020
Expires: December 9, 2021
30 minutes to complete

Accredited By

Target Audience

Rheumatologists, dermatologists, primary care providers, pulmonologists, and other health care providers who manage patients with ILD.

Learning Objectives

SSc-ILD

  • Diagnose SSc-ILD based on clinical impression and appropriate diagnostic tests
  • Discuss prevailing “dogma” for the diagnosis and management of SSc-ILD
  • Describe extrapulmonary manifestations and common comorbidities of SSc-ILD
  • Evaluate therapeutic options for the management of SSc-ILD in terms of efficacy and safety

PF-ILD

  • Identify the ILDs most commonly associated with a progressive fibrosing phenotype (PF-ILD)
  • Describe the signs and symptoms associated with PF-ILD
  • Describe the clinical course of a PF-ILD
  • Review the general therapeutic options available for the management of PF-ILDs
  • Discuss emerging therapeutic options for the management of PF-ILDs

Activity Description

Video reports on clinical trials, posters, and sessions from the virtual ACR 2020 conference. Faculty discuss the latest on systemic sclerosis-ILD, progressive fibrosing-ILD, and the implication of this information on current clinical practices for clinicians.

Faculty

S. Sam Lim, MD, MPH
Professor of Medicine and Epidemiology
Clinical Director, Division of Rheumatology
Emory University
Atlanta, GA


Elizabeth Volkmann, MD, MS
Clinical Instructor
Department of Medicine, Division of Rheumatology
University of California, Los Angeles
Los Angeles, CA


Daniel J. Wallace, MD, FACP, MACR
Associate Director, Rheumatology Fellowship Program
Professor of Medicine, Cedars-Sinai Medical Center
David Geffen School of Medicine Center
at University of California, Los Angeles
Los Angeles, CA

Conflict of Interest Policy/Disclosure Statement

The following staff at TFF report that they have relevant financial relationships to disclose:

  • Patrick Harty, PhD, reports that his spouse is employed by Pfizer, Inc. and they hold stock in Pfizer, Inc.

All other planners, reviewers, editors, staff, CME committee, and other members at TFF who control content have no relevant financial relationships to disclose.
 
The following faculty report that they have no relevant financial relationships to disclose:

  • Daniel J. Wallace, MD, FACP, MACR, has nothing to disclose

The following faculty report that they have relevant financial relationships to disclose:

  • S. Sam Lim, MD, MPH, has served as a consultant on the UCB Medical Advisory Board
  • Elizabeth Volkmann, MD, MS, has served as a consultant for Boehringer Ingelheim Pharmaceuticals, Inc. and Forbius

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Nurses who are certified by the American Nurses Credentialing Center (ANCC) may utilize activities that are certified by ACCME-accredited providers toward their requirement for certification renewal by the ANCC. A certificate of attendance will be provided by The France Foundation, an ACCME accredited provider.

Method of Participation/How to Receive Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity.
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form. This provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.

Statement of Commercial Support

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and the commercial supporter(s) assume no liability for the information herein.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Pages